AI Article Synopsis
Article Abstract
The effect of bopindolol on circadian blood pressure and heart rate profile was evaluated by means of an automatic recording technique (Pressurometer II). Blood pressure and heart rate was measured every 15 min for 24 h in 11 ambulant hypertensive patients. Recordings were made after 2 weeks on placebo then after treatment for 4 and 8 weeks with single daily doses of 0.5 or 1 mg bopindolol, according to a double-blind crossover plan. The results show a significant fall in the mean 24-h values for systolic and diastolic blood pressure and heart rate on both dosages of bopindolol. The low-dose level had a more marked effect on the day phase of the blood pressure profile, whereas the high-dose level affected day and night phases equally. Over all, the circadian rhythms of blood pressure and heart rate were not influenced. In conclusion, bopindolol has a well-defined antihypertensive effect on the various phases of the 24-h blood pressure and heart rate profiles.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00005344-198608006-00014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patient-Centered mHealth Intervention to Improve Self-Care in Patients With Chronic Heart Failure: Phase 1 Randomized Controlled Trial.
J Med Internet Res
January 2025
Indiana University, Indianapolis, IN, United States.
Background: Heart failure (HF) is one of the most common causes of hospital readmission in the United States. These hospitalizations are often driven by insufficient self-care. Commercial mobile health (mHealth) technologies, such as consumer-grade apps and wearable devices, offer opportunities for improving HF self-care, but their efficacy remains largely underexplored.
View Article and Find Full Text PDFIntraoperative Blood Pressure Misclassification Due to Inaccuracy of Noninvasive Oscillometric Cuff-Measured Blood Pressure.
Hypertension
February 2025
Department of Anesthesiology and Perioperative Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA (D.S.K., S.K., M.C.).
Equating Office and Ambulatory Blood Pressure.
Hypertension
February 2025
Division of General Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA (M.M.K., L.N., S.P.J.).
Temporal changes in hospital readmissions for postpartum hypertension in the US, 2010 to 2019; a serial cross-sectional analysis.
PLoS One
January 2025
Duke Center for Policy Impact in Global Health, Durham, North Carolina, United States of America.
Background: Hypertension is the most common primary diagnosis associated with postpartum readmissions within 42 days of delivery hospitalization. In the United States, nearly half of the cases of eclampsia, a severe form of preeclampsia, develop during the postpartum period, and the postpartum onset of hypertensive disorders of pregnancy, like antepartum hypertension poses long-term health risks to pregnant individuals, including an increased likelihood of developing overall cardiovascular disease, coronary heart disease, heart failure, and chronic hypertension. In this paper, we estimate the trends in the incidence of readmissions for postpartum hypertension within 42 days of delivery discharge in the US, disaggregated by median household income.
View Article and Find Full Text PDFUltrasound renal denervation in hypertensive patients: A systematic review and meta-analysis.
PLoS One
January 2025
Faculty of Medicine, Airlangga University, Surabaya, Indonesia.
Introduction: Hypertension is the leading noncommunicable disease case affecting 1.28 billion individuals worldwide, with most cases located in low- and middle-income countries. While there are numerous techniques for treating mild to moderate hypertension, properly controlling severe or resistant hypertension poses substantial challenges.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!